CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 22 enrolled
Drug / intervention
Combo Chelation with Deferasirox (Exjade) and Deferoxamine (DFO)drug
Likely dose
Combo Chelation with Deferasirox (Exjade) and Deferoxamine (DFO) 30 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00901199
NCT00901199Phase 2Completed
CompareCT.gov

Safety of Deferasirox (ICL670) and Deferoxamine (Desferal or DFO) Combined Chelation Therapy in Patients With Transfusion Dependent Thalassemia and Iron Overload

Elliott Vichinsky·interventional·Posted May 13, 2009·Updated Aug 12, 2021

In Brief

A Phase 2 clinical trial evaluating Combo Chelation with Deferasirox (Exjade) and Deferoxamine (DFO) for Thalassemia and Iron Overload. Completed, enrolled 22 participants across 1 site.

Detailed Summary

This is a pilot study looking at the safety and efficacy of giving combination chelation with deferasirox and deferoxamine. The hypothesis is that combination chelation is safe in decreasing overall iron in patients with thalassemia.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsThalassemia, Iron Overload
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMay 13, 2009
Enrollment StartSep 1, 2007
Primary CompletionOct 1, 2012
TodayJul 2, 2026
Enrollment to primary: 5.1 yearsPosted 17.1 years ago

Interventions

Combo Chelation with Deferasirox (Exjade) and Deferoxamine (DFO)drug

All subjects will be given Deferasirox 20-30 mg/kg for 7 days per week. All subject will be given Deferoxamine 50 mg/kg for 3-7 days per week. The number of days for Deferoxamine will be determined by liver iron concentration at baseline.